M. M. Batyushin, M. A. Trubnikova, G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, D. S. Polyakov, S. Sh. Akhmedkhanov, I. G. Bakulin, I. A. Bodrievskaya, I. A. Viktorova, N. G. Vinogradova, A. S. Galyavich, N. P. Garganeeva, N. Yu. Grigorieva, S. B. Erofeeva, M. A. Kercheva, S. G. Kechedzhieva, N. A. Koryagina, S. V. Malchikova, V. A. Nevzorova, S. V. Nedogoda, M. M. Petrova, V. A. Pogrebetskaya, A. P. Rebrov, O. A. Rubanenko, E. A. Safianik, V. V. Skibitsky, E. A. Smirnova, E. A. Starovoitova, R. F. Khamitov, A. I. Chesnikova, T. M. Shabatina, I. I. Shaposhnik, A. R. Vaisberg, A. V. Aparkina, I. N. Barykina, T. I. Batluk, R. A. Bashkinov, A. T. Beybalayeva, Y. A. Belenikina, O. A. Bilevich, Zh. V. Bondareva, A. Yu. Vaskin, T. V. Vlasova, E. V. Galko, T. U. Garifullin, E. D. Gordeychuk, E. V. Grigorieva, I. V. Gubareva, L. K. Danilova, A. I. Dolgushina, E. M. Durygina, D. S. Evdokimov, N. V. Zhdankina, E. I. Zheleznyak, D. S. Zueva, D. S. Ivanova, E. Yu. Ivanchenko, M. V. Kazakovtseva, A. A. Kaznina, N. A. Karoli, D. S. Kaskaeva, Z. F. Kim, M. V. Kozlova, Y. I. Kudrinskaya, A. S. Kuznetsova, E. Yu. Levchenko, I. A. Lukonin, V. O. Lutova, N. A. Magdeeva, E. V. Makarova, N. E. Makarova, M. M. Mamontova, E. S. Melnikov, A. F. Molostvova, T. D. Naborshchikova, I. N. Nikitina, D. P. Novikova, M. V. Novikova, V. I. Pakusina, K. G. Pereverzeva, I. S. Pleshakov, Yu. G. Pokramovich, O. V. Ponomareva, E. A. Popova, N. A. Popova, E. S. Potapova, E. D. Resnyanskaya, M. Yu. Rozhkova, A. O. Rubanenko, M. D. Rudoy, A. S. Salasyuk, L. M. Salimova, V. I. Samokhina, N. Sh. Sanginova, F. I. Sattarova, A. Kh. Safina, D. P. Sirotenko, N. S. Skarzhinskaya, A. V. Skibitsky, E. I. Suchkova, L. E. Tepnadze, A. V. Fendrikova, T. E. Filatova, O. V. Filyushin, O. Yu. Chizhova, T. I. Chudinovskikh, S. S. Yakushin, and E. M. Yashina
Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of markers (albuminuria (AU), decreased glomerular filtration rate (GFR)) and the prevalence of chronic kidney disease (CKD), which will provide information on the actual detection rate of CKD and the related markers in territories included in the registry of research centers.Material and methods. The article presents the first data from the AURA registry. Recruitment was carried out from March 6, 2023 to January 23, 2024. Thirty-four research centers in various federal districts of the Russian Federation and 104 doctors took part in the recruitment. We included 4580 subjects over the age of 40 years who had no previously established diagnosis of CKD and did not have type 1 or type 2 diabetes. During recruitment, the researchers were guided by the AURA study protocol (Version 1.7/12-26-2022).Results. AU more than 20 mg/g was detected in 64,9% of cases. At the same time, AU is more common at GFR values that may correspond to stage 3A of CKD. The rarer occurrence of AU in those examined with GFR >60 ml/min/1,73 m2 may be explained by less severe renal damage at this CKD stage. The incidence of AU was significantly higher in men, older people, smokers, people with metabolic syndrome, hypertension (HTN), prediabetes and overweight. The occurrence of AU also increased as HTN grade increased. AU detection rate was associated with hypertriglyceridemia, a high blood level of C-reactive protein, which is an integrative marker of inflammation that negatively affects cardiovascular risk.Conclusion. The presented first data from the AURA registry demonstrated the high AU prevalence in people over 40 years of age. A high incidence of AU was typical for patients with HTN, coronary artery disease, atrial fibrillation, heart failure, and prediabetes. An association has been demonstrated between the high incidence of AU and male sex, age, overweight, hyperuricemia, dyslipidemia, and a number of other cardiovascular risk factors.